Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2020-05-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于第二大股东部分股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's second largest shareholder. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company shares, and other related information. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge (a form of capital/financing update) but does not describe a new financing round or capital structure change in detail. It is not a full financial report or earnings release. Given the nature of the announcement about share pledge, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2020-05-22 Chinese
2019年年度报告摘要（更新后）
Annual Report Classification · 95% confidence The document is titled as the "2019 Annual Report Summary" of Beijing SL Pharmaceutical Co., Ltd. It contains detailed information about the company's business, products, industry status, and development plans for the year 2019. The content includes comprehensive descriptions of the company's operations, product lines, research and development, production, sales, and industry outlook, which are typical components of an annual report. The document length is substantial (15,000 characters), indicating it is not a brief announcement or a simple notice. There is no indication that this is a certification, voting result, or a presentation. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-05-22 Chinese
2019年年度报告及摘要的更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding the 2019 Annual Report and its summary for Beijing SL Pharmaceutical Co., Ltd. It specifies corrections to shareholder numbers previously disclosed in the annual report and summary. The document is short (1078 characters) and states that the corrected reports have been re-disclosed on the official information disclosure website. This indicates that the document itself is not the full annual report but an announcement correcting and referring to the annual report. According to the 'MENU VS MEAL' rule, such a correction notice is best classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K) itself.
2020-05-22 Chinese
2020年第一季度报告正文（更新后）
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2020 年第一季度报告正文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2020 First Quarter Report." It contains detailed financial data for the first quarter of 2020, including revenue, net profit, earnings per share, asset and equity figures, and other financial metrics. The document also includes sections on shareholder information, non-recurring gains and losses, entrusted financial management, and other operational details. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) clearly indicates this is an Interim / Quarterly Report. The document length (6495 characters) is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2020
2020-04-29 Chinese
2020年第一季度报告全文（更新后）
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2020 年第一季度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2020 First Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow data, and shareholder information for the first quarter of 2020. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-29 Chinese
2019年年度报告（已取消）
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2019 年年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2019 Annual Report Full Text." It contains detailed sections including company overview, financial data for the year 2019, business summary, management discussion, and financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial figures, management statements, risk factors, and detailed business operations, all typical of an official annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-04-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.